2,168
Views
4
CrossRef citations to date
0
Altmetric
Research Article

On the molecular structure of Remdesivir for the treatment of Covid-19

, ORCID Icon &
Pages 995-1002 | Received 22 Jul 2020, Accepted 09 Dec 2020, Published online: 27 Dec 2020
 

Abstract

(SARS-CoV-2), was first identified in December 2019 as the cause of a respiratory illness designated coronavirus disease 2019, or Covid-19. Several therapeutic agents have been evaluated for the treatment of Covid-19, but none have yet been shown to be efficacious. Remdesivir (GS-5734), an inhibitor of the viral RNA-dependent, RNA polymerase with inhibitory activity against SARS-CoV and the Middle East respiratory syndrome (MERS-CoV), was identified early as a promising therapeutic candidate for Covid-19 because of its ability to inhibit SARS-CoV-2 in vitro. Besides, in nonhuman primate studies, remdesivir initiated 12 hours after inoculation with MERS-CoV9,10 reduced lung virus levels and lung damage. In the field of Medical Science, concerning the definition of the topological index on the molecular structure and corresponding medical, biological, chemical, pharmaceutical properties of drugs can be studied by the topological index calculation. In this paper, we compute some of the general temperature topological properties of remdesivir that the results in this paper may be useful in finding new drug and vaccine for the treatment and prevention of COVID-19.

AMS Subject Classification:

Availability of data and materials

The data involved in the examples of our manuscript are included within the article.

Author details

Department of Mathematics, Azarbaijan Shahid Madani University, Tabriz, Iran and Institute of Computing Science and Technology, Guangzhou University, Guangzhou, China.

Disclosure statement

The author declares that they have no competing interests.

Additional information

Funding

This work has been financially supported by Azarbaijan Shahid Madani University under the grant number ASMU/6/98. The third author is supported by the National Key R & D Program of China (Grant no. 2019YFA0706402).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.